Brominated Flame Retardants vs Recombinant Bovine Growth Hormone: which is worse?

What is Brominated Flame Retardants?

Brominated flame retardants (BFRs) are a class of synthetic chemicals added to consumer products and materials to reduce flammability. They include polybrominated diphenyl ethers (PBDEs), hexabromocyclododecane (HBCD), and others. While not direct food additives, they contaminate the food supply through environmental pathways and food packaging.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Brominated Flame Retardants: PBDEs and other BFRs are endocrine disruptors, neurodevelopmental toxicants, and probable carcinogens. They accumulate in human adipose tissue, breast milk, and blood. PBDEs were found in 100% of samples in multiple US population biomonitoring studies. US women have PBDE body burdens 10-100 times higher than European women, reflecting the US's historically heavy PBDE use before bans. Neurodevelopmental effects: multiple studies have associated prenatal PBDE exposure with lower IQ, attention deficits, and behavioral problems in children. A 2012 Environmental Health Perspectives study found inverse associations between PBDE cord blood levels and child IQ and behavioral outcomes. Thyroid disruption: BFRs structurally mimic thyroid hormones and compete with thyroid hormone binding proteins, disrupting the thyroid axis — critical for fetal brain development. Carcinogenicity: some PBDEs are associated with thyroid cancer risk in human studies. PBDEs enter the food supply primarily through fatty fish (salmon, tuna), meat, dairy, and some contaminated produce from biosolid-amended soils.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.